84 results
Page 2 of 5
6-K
EX-99.2
3tq1k
11 May 23
Current report (foreign)
8:00am
6-K
EX-99.3
f2rdwukg4mht9bbtrmv
11 May 23
Current report (foreign)
8:00am
424B5
xijncbxqts7d jabczu
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
5i69cojjxsp e8
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
wiwwe n1u
9 Nov 22
Current report (foreign)
7:53am
6-K
EX-99.2
du2 z0lq4jjtzgfazx
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.4
hcc 6z6kdp5rypktzb
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.3
8qs g5d894z
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.2
2vuhvn
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.2
c8z iq5mrxwzx
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
o42fu9rzagak1bxe9gh
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.3
ec3s3v
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
6v2t2 rdm
24 Mar 22
InflaRx Reports Full Year 2021 Financial and Operating Results
8:40am
6-K
EX-99.1
c1pyj8vhru0x8l7grj1s
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
EX-99.2
qvf58ge877sd
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
g7v 1cw2x
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
EX-99.2
y8dv1
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.2
4bzq6dq059h3fk3
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.2
p9dsx9x 1ok515
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am